TBP Pharma is ready to take C3 to the next level – clinical trials. We believe a high probability of success in human FDA Phase I clinical trials exists:

  • Low likelihood of compound accumulating in humans due to multiple routes of clearance
  • The C3 molecule is excreted from the body intact
  • C3 compound has a plasma half-life of 8 hours, and has high renal and hepatic clearance
  • C3 is not metabolized in mammals

The Company has an active private placement memorandum for investors that meet SEC qualifying regulations. If interested, please contact us for the appropriate paperwork.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>